Compare Ascendis Pharma A/S (ASND) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Freshworks Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Freshworks Inc trades at $10.45 (market cap $2.86B). The key difference: Ascendis Pharma A/S is far larger — about 6.2× Freshworks Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FRSH | |
|---|---|---|
Market Cap | $17.74B | $2.86B |
Sector | Health | Technology |
52-Week High | $277.18 | $14.77 |
52-Week Low | $163.32 | $6.88 |
Enterprise Value | $18.11B | $2.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FRSH trades at $10.36, down 0.38% on the day, with a bullish technical signal from moving averages and an overall analyst consensus split evenly between Buy and Hold. The company reported strong revenue growth to $838.81M in 2025, turning profitable with a net income of $183.72M, and recently announced Q2 2026 earnings will be released on August 4, 2026. Recent news highlights include a partnership with Vanquis and AI product enhancements.
Outlook remains positive with Wall Street projecting a 26% upside, supported by robust cash flow and margin expansion. Key risks include competitive pressures in SaaS and execution on AI initiatives. The stock presents a value opportunity given its P/E of 16.86 versus sector averages, but investors should monitor Q2 earnings for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
